BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition
Apoptosis · 2024-12 · 29 (11-12) · 2197-2213
DOI: 10.1007/s10495-024-02014-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apoptosis, online erschienen am 02.09.2024. Verfasst von N V Pervushin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Russian Science Foundation, Cancerfonden, Cancerföreningen i Stockholm.
Abstract (Originalsprache)
The development of drug resistance reduces the efficacy of cancer therapy. Tumor cells can acquire resistance to MDM2 inhibitors, which are currently under clinical evaluation. We generated RG7388-resistant neuroblastoma cells, which became more proliferative and metabolically active and were less sensitive to DNA-damaging agents in vitro and in vivo, compared with wild-type cells. The resistance was associated with a mutation of the p53 protein (His193Arg). This mutation abated its transcriptional activity via destabilization of the tetrameric p53-DNA complex and was observed in many cancer types. Finally, we found that Cisplatin and various BH3-mimetics could enhance RG7388-mediated apoptosis in RG7388-resistant neuroblastoma cells, thereby partially overcoming resistance to MDM2 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
- Faculty of Medicine, MV Lomonosov Moscow State University, Moscow, 119991, Russia.
- Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, Moscow, 119991, Russia.
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, 119234, Russia.
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia.
- Moscow Center for Advanced Studies, Moscow, 123592, Russia.
Förderung
- The Russian Science Foundation
- Cancerfonden
- Cancerföreningen i Stockholm
- Karolinska Institute
Zitieren
APA
Pervushin, N. V., Nilov, D. K., Pushkarev, S. V., Shipunova, V. O., Badlaeva, A. S., Yapryntseva, M. A., Kopytova, D. V., Zhivotovsky, B., & Kopeina, G. S. (2024). BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition. Apoptosis, 29(11-12), 2197-2213. https://doi.org/10.1007/s10495-024-02014-8
Vancouver
Pervushin NV, Nilov DK, Pushkarev SV, Shipunova VO, Badlaeva AS, Yapryntseva MA, et al. BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition. Apoptosis. 2024;29(11-12):2197-2213. doi:10.1007/s10495-024-02014-8
BibTeX
@article{Pervushin2024,
author = {Pervushin, N V and Nilov, D K and Pushkarev, S V and Shipunova, V O and Badlaeva, A S and Yapryntseva, M A and Kopytova, D V and Zhivotovsky, B and Kopeina, G S},
title = {BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition},
journal = {Apoptosis},
year = {2024},
volume = {29},
number = {11-12},
pages = {2197--2213},
doi = {10.1007/s10495-024-02014-8}
}
EUVIMED